Nektar Announces Initiation of Investigator-Initiated Trial Evaluating ... PharmaLive (press release) (subscription) Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC). Share. SAN FRANCISCO, Feb. 5, 2013 /PRNewswire ... |